Drug Trial Radar · NCT03252340
Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Feb 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Sep 19, 2017
Primary completion
Aug 17, 2022
Study completion Sep 27, 2022
Sponsor
- Lead sponsor
- EHL Bio Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 17, 2017
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate safety in subjects with over moderately subacute and chronic atopic dermatitis after an intravenous injection of ADSTEM Inj. Since this is an observational study of patients participated in Phase 1 clinical trials, no drug is administered in this study.
Conditions
- Atopic Dermatitis
Interventions
ADSTEM Inj.Drug
1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial. 2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tumor formationTime frame: 60months after treatment of ADSTEM Inj.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chungnam National University Hospital
Daejeon, Chungcheongnam-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.